drug_type
RELEVANT_DRUG
intervention_type
Cellular (CAR T) therapy
drug_description
Autologous gene-modified T cells expressing chimeric antigen receptors targeting CD19 and BCMA to deplete B cells and plasmablasts/plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express dual chimeric antigen receptors targeting CD19 and BCMA. Upon antigen engagement, the CAR T cells become activated and lyse CD19+ B cells and BCMA+ plasmablasts/plasma cells (via cytotoxic pathways and cytokine release), depleting autoreactive B-lineage compartments to reduce autoantibody production and reset humoral immunity.
drug_name
RD06-05 (dual CD19/BCMA CAR T)
nct_id_drug_ref
NCT06548607